One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Clinical leaders and providers’ perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs’ facilities
Eric J. Hawkins, Anissa N. Danner, Carol A. Malte, Brittany E. Blanchard, Emily C. Williams, Hildi J. Hagedorn, Adam J. Gordon, Karen Drexler, Jennifer L. Burden, Jennifer Knoeppel, Aline Lott, George G. Sayre, Amanda M. Midboe & Andrew J. Saxon
doi : 10.1186/s13722-021-00263-5
Addiction Science & Clinical Practice volume 16, Article number: 55 (2021)
Improving access to medication treatment of opioid use disorder (MOUD) is a national priority, yet common modifiable barriers (e.g., limited provider knowledge, negative beliefs about MOUD) often challenge implementation of MOUD delivery. To address these barriers, the VA launched a multifaceted implementation intervention focused on planning and educational strategies to increase MOUD delivery in 18 medical facilities. The purpose of this investigation was to determine if a multifaceted intervention approach to increase MOUD delivery changed providers’ perceptions about MOUD over the first year of implementation.
Integrating traditional practices and social network visualization to prevent substance use: study protocol for a randomized controlled trial among urban Native American emerging adults
Elizabeth J. D’Amico, Daniel L. Dickerson, Anthony Rodriguez, Ryan A. Brown, David P. Kennedy, Alina I. Palimaru, Carrie Johnson, Rosanna Smart, David J. Klein, Jennifer Parker, Keisha McDonald, Michael J. Woodward & Ninna Gudgell
doi : 10.1186/s13722-021-00265-3
Addiction Science & Clinical Practice volume 16, Article number: 56 (2021)
Nonmedical use of prescription opioids (defined as taking opioid medications for hedonic effects or in a manner other than prescribed) and the use of heroin have emerged in recent years as major public health concerns in the United States. Of particular concern is the prevalence of opioid use among emerging adults (ages 18–25), as this is a developmental period of heightened vulnerability and critical social, neurological, and psychological development. Data from 2015 show that American Indian/Alaska Native (AI/AN) people have the highest rates of diagnosis for opioid use disorders (OUDs). One recent study found that the overdose death rate among urban-dwelling AI/AN individuals was 1.4 times higher compared to those living in rural areas. To date, there are no evidence-based prevention programs addressing opioid use among urban AI/AN emerging adults that integrate culturally-appropriate strategies with evidence-based treatment. Traditions and Connections for Urban Native Americans (TACUNA) builds on our prior work with AI/AN communities across California to develop and evaluate culturally appropriate programming to address opioid, alcohol, and cannabis use among urban AI/AN emerging adults.
Care-engaged individuals with polysubstance use in Northeastern US are undertreated for methamphetamine use disorder: a retrospective cohort study
Mimi Yen Li, George A. Alba, Julian Mitton & Benjamin Bearnot
doi : 10.1186/s13722-021-00267-1
Addiction Science & Clinical Practice volume 16, Article number: 57 (2021)
Stimulant use has increased across the US, with concomitant opioid and methamphetamine use doubling between 2011 and 2017. Shifting patterns of polysubstance use have led to rising psychostimulant-involved deaths. While it is known that individuals who use methamphetamine require greater access to treatment, there is still little known about methamphetamine use and treatment among individuals who are already engaged in outpatient substance use treatment.
Correction to: Reimagining brief interventions for alcohol: towards a paradigm fit for the twenty first century
Jim McCambridge
doi : 10.1186/s13722-021-00270-6
Addiction Science & Clinical Practice volume 16, Article number: 58 (2021)
A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting
Halle G. Sobel, Jill S. Warrington, Samuel Francis-Fath, Abigail M. Crocker & Claudia A. Berger
doi : 10.1186/s13722-021-00264-4
Addiction Science & Clinical Practice volume 16, Article number: 59 (2021)
Urine drug screening (UDS) is commonly used as part of treatment for opioid use disorder (OUD), including treatment with buprenorphine-naloxone for OUD in a primary care setting. Very little is known about the value of UDS, the optimum screening frequency in general, or its specific use for buprenorphine treatment in primary care. To address this question, we thought that in a stable population receiving buprenorphine-naloxone in the primary care setting it would be useful to know how often UDS yielded expected and unexpected results.
